ALGN — Align Technology, Inc.

Is ALGN overbought or oversold? Here is the current MarketMoodz read.

Healthcare · Medical Instruments & Supplies

Oversold As of November 17, 2026

Align Technology, Inc. (ALGN) currently reads Oversold on the MarketMoodz overbought/oversold meter, as of November 17, 2026. The Healthcare name (Medical Instruments & Supplies) last closed at $163.46. The rating moved from Neutral to Oversold on November 16, 2026.

See all oversold Healthcare stocks →

AI analysis

Align Technology, Inc. (ALGN) combines a dominant clear‑aligner franchise with an installed digital scanner/software ecosystem that drives recurring procedure volumes and attractive consumable margins. Near‑term catalysts include continued international penetration, increased iTero install base monetization, and cross‑sell into restorative workflows; structural tailwinds come from broader adoption of digital dentistry. Main challenges are demand cyclicality, growing competition and potential regulatory or reimbursement headwinds; execution on international scaling and margin maintenance will determine the path to sustained outperformance.

Key factors

  • Market leadership in clear aligners with strong brand recognition and high share of orthodontic case starts globally
  • Integrated ecosystem (iTero scanners, software, clear aligners) that drives recurring procedure volume and cross‑sell opportunities
  • Healthy margin profile driven by proprietary consumables and digital workflow services
  • Ongoing international expansion and penetration into restorative and clear aligner adjacencies supporting multi‑year revenue growth
  • Solid free cash flow generation and balance sheet flexibility to fund R&D, M&A, and potential shareholder returns
  • Favorable structural demand from continued adoption of digital dentistry and patient preference for esthetic orthodontic solutions

Risks

  • Demand sensitivity to consumer discretionary spending and macroeconomic slowdowns that can delay elective dental procedures
  • Intensifying competition and potential price compression from incumbents, direct‑to‑consumer entrants, and regional competitors
  • Regulatory, reimbursement or professional pushback in key markets that could limit clinical adoption or channel economics
  • Execution risk around international expansion, supply chain disruptions, and scaling costs for scanner and manufacturing deployments
  • Litigation or IP disputes related to aligner technology or clinical claims
  • Foreign exchange exposure and geopolitical risks impacting overseas sales and margins

Latest MarketMoodz coverage

See today's live rating, score and targets

Members see the live hourly rating for ALGN — the numeric AI score plus targets and entry zones — while this public page updates nightly.

Start the 14-day trial

This page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.